巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    KemPharm

    KMPH
    4.530
    0.140
    3.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・KemPharm - 延遲價格・最後更新於 28/06 9:30
    最高位
    4.780
    最低位
    4.530
    開市價
    --
    前收市價
    4.670
    成交量(千)
    6.63
    成交額(百萬)
    0.28
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    155.94
    市盈率
    13.730
    息率
    --
    差價
    --
    52週高低
    14.010 - 4.000
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    KemPharm
    證券代碼
    KMPH.US
    所屬板塊
    Biotechnology
    公司業務
    KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of treatments for the central nervous system, CNS, and rare disease indications. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, and KP484, which are both based on a prodrug of d-methylphenidate, or d-MPH; KP879, is also based on a prodrug of d-MPH.
    發行量
    34422503
    公司總部
    1180 Celebration Boulevard, Suite 103
    公司網址
    https://www.kempharm.com
    公司電郵
    info@kempharm.com
    公司電話
    +1 321 939-3416
    暫無內容

    關於

    KemPharm(KMPH.US)所屬的行業板塊為Biotechnology。
    KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of treatments for the central nervous system, CNS, and rare disease indications. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, and KP484, which are both based on a prodrug of d-methylphenidate, or d-MPH; KP879, is also based on a prodrug of d-MPH.
    詳細公司背景可參考: https://www.kempharm.com